Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT04878432 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome (MDS)

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Start date: March 17, 2022
Phase: Phase 2
Study type: Interventional

Main objective of this study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))

NCT ID: NCT04872595 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects. Participants in this study will be children and adults who have acute leukemia or myelodysplastic syndrome (MDS), and will receive a standard conditioning regimen to prepare the body for an allogeneic hematopoietic cell transplant (allo-HCT). The conditioning regimen will include r-ATG, one of two combinations of chemotherapy, and possibly total body irradiation (TBI).

NCT ID: NCT04745676 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Start date: March 25, 2021
Phase: N/A
Study type: Interventional

This is a pilot study to evaluate the usability and feasibility of a telehealth-delivered advance care planning intervention among 20 older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), their caregivers, and oncologists.

NCT ID: NCT04668885 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Start date: January 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after Hypomethylating Agents (HMA) failure.

NCT ID: NCT04609826 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

DHODH
Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.

NCT ID: NCT04603001 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

NCT ID: NCT04582539 Active, not recruiting - Multiple Myeloma Clinical Trials

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

LIMBER
Start date: August 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

NCT ID: NCT04478227 Active, not recruiting - Thrombocytopenia Clinical Trials

TPO-Mimetic Use in Children for Hematopoietic Failure

Start date: August 18, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.

NCT ID: NCT04477850 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) in Chinese and Japanese participants with ring sideroblasts who require Red Blood Cells (RBC) transfusions.

NCT ID: NCT04477291 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Start date: October 6, 2020
Phase: Phase 1
Study type: Interventional

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.